Loading market dashboard
Boston Scientific Corporation
BSXHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Share buybacks are one of the key ways that companies express confidence in their outlook. This is particularly true when shares take a large hit, as management teams look to retire shares at what they may believe is a depressed price.
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian Federal Prosecution Service (“MPF”) in civil public action No. 1002764-28.2025.4.01.3903 before the Federal Court of Altamira, Pará, Brazil.
Weak guidance, analyst target cuts and declining energy prices weighed on Zscaler, AutoZone, PDD Holdings and other large-cap stocks, making them last week's biggest losers.
Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Sales of a key product line will likely be flat this quarter and next, company management said.
Boston Scientific (BSX) concluded the recent trading session at $49.11, signifying a -2.68% move from its prior day's close.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Pre-Market Stock Futures: Futures are trading lower on Thursday as new records are set almost daily, with the AI/Data center trade continuing to push stocks higher on Wednesday. All four major indices hit or closed Wednesday's session at record highs, with the legacy Dow Jones Industrial Average leading the way, up 0.36% at 50,664, setting... Here Are Thursday's Top Wall Street Analyst Research Calls: Agilent, Boston Scientific, Comfort Systems, Dick's Sporting Goods, Dominion Energy, Electronic Arts, First Solar, Trade Desk, Valvoline, and More
The Bank of N.T. Butterfield and Son Limited (âButterfieldâ) (NYSE: NTB | BSX: NTB.BH) has entered into a definitive agreement to acquire CIBC's 91.7% intere
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.
The medical device giant just opened its wallet for a stake in a privately held company with a groundbreaking product.
On May 27, 2026, we delve into the DCF analysis for Boston Scientific Corp (BSX), a company currently facing significant price performance challenges. Over the
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election as a director of Belo Sun at the Company's Annual and Special Meeting of Shareholders held on May 26, 2026 (the “Meeting”), was elected.
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th Panel of the Federal Regional Court of the 1st Region (“TRF-1”) in relation to three judicial proceedings involving the Volta Grande Gold Project (the “Project”), located in Pará State, Brazil. DPU Appeal Dismissed One of the matters heard concerned the appeal filed by the Federal Public Defender's Office (“DPU”) and an indigenous association against a lower court decision that had dismissed for procedural reasons a civil public action related to the alleged need for supplementation of the Indigenous Component Study (“ECI”) and the performance of additional public consultation procedures.
Boston Scientific Corporation (NYSE:BSX) on Tuesday reported positive pivotal trial data for its investigational SEISMIQ 4CE Coronary Intravascular Lithotripsy catheter, with the device meeting both primary safety and effectiveness goals in patients with severely calcified coronary artery disease.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD).
On May 18, 2026, Boston Scientific Corp (BSX) shares rose 6.2%, bringing the current price to $55.92. This increase comes amid a challenging year for the compan
BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.
Boston Scientific Corporation (NYSE:BSX) said it invested $1.5 billion in privately held MiRus, securing an approximately 34% equity stake and an exclusive option to acquire the company's investigational transcatheter aortic valve replacement (TAVR) business.
U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held MiRus LLC in return for a 34% equity stake and potential access to the startup's heart-valve business.
MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of its common stock, as part of its previously announced $5 billion share repurchase authorization.
Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has invested $1.5 billion in return for an approximately 34% equity stake in MiRus LLC, a privately-held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system.
Boston Scientific is down over 43% YTD, erasing years of gains amid guidance cuts and segment-specific weakness. I initiate BSX with a Buy rating, citing achievable guidance post-Q1 reset and easing sales comps in 2H, which could stabilize the stock. Key risks include further guidance cuts, persistent WATCHMAN and Urology segment weakness, and macro-driven procedure slowdowns.
Miami International Holdings Announces Participation in Upcoming June Investor Conferences PR Newswire MIAMI and
BSX expands global reach with strong APAC growth, FARAPULSE momentum and new approvals driving gains across Europe and China.
Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.
On May 13, 2026, we delve into a DCF analysis for Boston Scientific Corp (BSX), a company that has seen significant price fluctuations recently. The stock has e
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Gold Project (“Project”) located in Pará State, Brazil, with the engagement of a mining consultant and the hiring of a Engineering Director.
Boston Scientific Corporation is a leading medtech innovator facing recent share price underperformance due to market share erosion in electrophysiology and sector-wide sentiment shifts. Despite competitive pressures, BSX maintains strong leadership in PFA, with Watchman and neuromodulation as promising growth drivers and a robust pipeline supported by strategic M&A. Management has improved operating and net margins, reduced short-term debt, and achieved ROIC above WACC, signaling efficient capital allocation and resilience despite slowing revenue growth.
Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.
On May 08, 2026, we delve into the DCF analysis for Boston Scientific Corp (BSX), a company that has faced significant price performance challenges recently. Th
Boston Scientific has issued an urgent recall to correct several heart devices after the U.S. Food and Drug Administration classified the action as its most serious recall, the regulator said on Thursday.
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQX: BSXGF) is pleased to announce that effective today, its common shares have qualified to trade on the OTCQX® Best Market (“OTCQX”) in the United States under the ticker “BSXGF”. The Company's common shares will continue to trade on the TSX Exchange under the symbol “BSX”.
ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
NEW YORK--(BUSINESS WIRE)---- $BSX #BSX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Geo.
In Q1 2026, Polen Focus Growth Portfolio returned -17.27% (net of fees) compared to -9.78% for the Index. Starbucks was the top performing absolute and relative contributor in Q1 amid positive signs that CEO Brian Nicol's multi-year turnaround strategy is beginning to bear fruit. In Q1 2026, we initiated new positions in Lam Research, Meta and Rollins, while we sold our holdings in Abbott Laboratories, Adobe, and Boston Scientific, Paycom and Intuit.
New York, New York--(Newsfile Corp. - May 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
MARLBOROUGH, Mass., May 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026.
Don't let their current weakness deter you. Sometimes, investors collectively misread and misprice the situation.
NEW YORK, May 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”), of the important May 4, 2026 lead plaintiff deadline.
New York, New York--(Newsfile Corp. - May 3, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
NEW YORK, May 03, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Boston Scientific Corporation (NYSE: BSX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Boston Scientific securities between July 23, 2025, and February 3, 2026, both dates inclusive (the "Class Period").
New class action for Boston Scientific (BSX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/4/2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 3, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, May 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. So what: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
New York, New York--(Newsfile Corp. - May 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
BENSALEM, Pa., May 1, 2026 /PRNewswire/ -- The Law Offices of Howard G.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 1, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Boston Scientific Corporation (NYSE: BSX).
New York, New York--(Newsfile Corp. - April 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
